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PrefaceUS Renal Data System 2018 Annual Data Report:
Epidemiology of Kidney Disease in the United
States
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Carola-Ellen Kleine, MD, Csaba P. Kovesdy, MD, William Krueter, MPA, Vivian Kurtz, MPH, Yiting Li, MPH,
Sai Liu, MPH, Maria V. Marroquin, Keith McCullough, MS, PhD, Miklos Z. Molnar, MD, PhD, Zubin Modi, MD,
Maria Montez-Rath, PhD, Hamid Moradi, MD, Hal Morgenstern, PhD, Purna Mukhopadhyay, PhD,
Brahmajee Nallamothu, MD, Danh V. Nguyen, PhD, Keith C. Norris, MD, Ann M. O’Hare, MD,
Yoshitsugu Obi, MD, PhD, Christina Park, MPH, Jeffrey Pearson, MS, Ronald Pisoni, PhD,
Praveen K. Potukuchi, MS, PharmD, Kaitlyn Repeck, MS, Connie M. Rhee, MD, MSc, Douglas E. Schaubel, PhD,
Jillian Schrager, MPH, David T. Selewski, MD, Ruth Shamraj, MA, Sally F. Shaw, DrPH, MPH,
Jiaxiao M. Shi, PhD, Monica Shieu, MPH, John J. Sim, MD, Melissa Soohoo, MPH, Diane Stefﬁck, MA, PhD,
Elani Streja, MPH, PhD, Keiichi Sumida, MD, Manjula Kurella Tamura, MD, MPH, Anca Tilea, MPH,
Megan Turf, BA, Dongyu Wang, MS, Wenjing Weng, MPH, Kenneth J. Woodside, MD, April Wyncott, MBA,
MPH, Jie Xiang, PhD, Xin Xin, MA, Maggie Yin, MA, Amy S. You, MS, Xiaosong Zhang, MS, Hui Zhou, PhD, MS,
and Vahakn Shahinian, MDThe US Renal Data System (USRDS) remains the largestand most comprehensive resource for those seeking
detailed information, data, and trends on a wide variety of
kidney disease topics covering both end-stage renal disease
(ESRD) and earlier stages of chronic kidney disease (CKD).
Supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) at the National
Institutes of Health and the Centers for Medicare &
Medicaid Services, the USRDS Coordinating Center has
operated from the Kidney Epidemiology and Cost
Center (KECC) at the University of Michigan, in partner-
ship with Arbor Research Collaborative for Health, in
Ann Arbor, Michigan, since 2014. The annual report is
published both online (www.usrds.org), and as a
supplement to AJKD.
Trends in the prevalence of CKD and ESRD are impor-
tant for health care policy and planning. According to
data from the National Health and Nutrition Examination
Survey (NHANES), the prevalence of CKD among US
adults is estimated at just under 15%, indicating that over
30 million American adults may have CKD. This is likely
due to the high prevalence of risk factors for the disease,
including an aging population, diabetes, hypertension,
obesity, cardiovascular disease, and other conditions.
The report highlights the fact that US rates for ESRD
(ie, dialysis or transplantation) rank among the highest in
the world, and continue to rise. In 2016, there were
124,675 new cases registered as ESRD, compared to
124,111 new cases the prior year. The prevalence of ESRD
continues to rise and reached 726,331 in 2016. Addi-
tionally, there are many “hot spots” of the conditionAJKD Vol 73 | Iss 3 | Suppl 1 | March 2019around the country as highlighted in the maps and tables
contained in the Annual Data Report.
Caring for those with kidney disease is expensive. The
total Medicare spending on both CKD and ESRD patients
was in excess of $114 billion in 2016. Accompanying
chronic diseases such as diabetes and heart failure com-
pound the cost of caring for these individuals.
In sharp contrast to this high burden and cost, the
USRDS continues to highlight low awareness about the
presence of the condition among patients with laboratory
evidence of early stages of kidney disease (CKD stages
1-3). Encouragingly, in recent years, there has been some
increase in awareness among those with CKD stage 4.
In the newly expanded chapter on hospitalization, the
trend in falling hospitalization rates is shown to be coun-
tered by rising rates of emergency room visits and short-
term observation stays for those on dialysis. A new chapter
on CKD among children and adolescents is introduced in
the 2018 USRDS Annual Data Report, along with the continued
extensive coverage of ESRD among children, adolescents,
and young adults. The international comparisons chapter
now includes descriptive ESRD data from over 70 countries.
A decrease in the kidney transplant waiting list by 3% over 2
successive years is a noteworthy observation—very likely
the result of recent changes in the kidney allocation system.
We hope that researchers, practitioners, and policy
makers will continue to derive value not only from
the Annual Data Reports, a regularly updated comprehensive
resource for epidemiology of kidney disease in the nation,
but also from the data-provisioning activities of the USRDS
and assistance to researchers through its help desk.Svii
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